Hull and East Yorshire Eye Hospital, United Kingdom.
J Refract Surg. 2012 Sep;28(9):614-9. doi: 10.3928/1081597X-20120809-01.
To evaluate the visual outcomes, efficacy, predictability, and short-term safety of implanting the Sulcoflex (Rayner Intraocular Lenses Ltd) intraocular lens (IOL) to correct residual pseudophakic errors.
Retrospective study of patients undergoing implantation of the Sulcoflex IOL. Uncorrected (UDVA) and corrected (CDVA) distance visual acuity and refractive outcomes were evaluated. Postoperative follow-up was at 1 week and 1, 3, 6, and 12 months.
Fifteen eyes (13 patients) were evaluated. Mean follow-up was 20 months (range: 14 to 30 months). The Sulcoflex aspheric (653L) and toric (653T) IOLs were implanted in 3 and 12 eyes, respectively. Preoperatively, mean logMAR (Snellen) UDVA and CDVA were 0.44 (20/55) and 0.05 (20/22), respectively. At 3 months, all eyes achieved logMAR UDVA of 0.20 (20/32) or better, with 10 (67%) eyes achieving UDVA of 0 (20/20) or better. Preoperative mean spherical and astigmatic errors were 1.07±0.83 diopters (D) and -1.45±0.98 D, respectively. Preoperative mean spherical equivalent refraction was -0.54±1.11 (D). Postoperative mean sphere and astigmatism at 3 months were -0.25±0.38 D and -0.50±0.57 D, respectively. Postoperative mean spherical equivalent refraction at 3 months was -0.15±0.28 D. All patients were within 1.00 D of attempted correction, with 93% within 0.50 D. Linear regression analysis showed good correlation (R²=0.72) between attempted versus achieved spherical equivalent refractions. No significant intra- or postoperative complications occurred.
Implantation of the Sulcoflex IOL was found to be an effective and predictable option for enhancing postoperative refractive results and reducing spectacle dependence for distance after surgery. The IOL was well tolerated in all eyes.
评估植入 Sulcoflex（Rayner 眼内晶状体有限公司）人工晶状体（IOL）矫正残余假性近视的视力结果、疗效、可预测性和短期安全性。
对植入 Sulcoflex IOL 的患者进行回顾性研究。评估未矫正（UDVA）和矫正（CDVA）远距视力和屈光结果。术后随访时间为 1 周、1、3、6 和 12 个月。
共评估了 15 只眼（13 例患者）。平均随访时间为 20 个月（范围：14 至 30 个月）。植入 Sulcoflex 非球面（653L）和散光（653T）IOL 分别为 3 只眼和 12 只眼。术前平均 logMAR（Snellen）UDVA 和 CDVA 分别为 0.44（20/55）和 0.05（20/22）。3 个月时，所有眼均达到 logMAR UDVA 0.20（20/32）或更好，10 只眼（67%）达到 UDVA 0（20/20）或更好。术前平均球镜和散光误差分别为 1.07±0.83 屈光度（D）和-1.45±0.98 D。术前平均等效球镜屈光度为-0.54±1.11（D）。术后 3 个月时平均球镜和散光分别为-0.25±0.38 D 和-0.50±0.57 D。术后 3 个月时平均等效球镜屈光度为-0.15±0.28 D。所有患者均在 1.00 D 的目标矫正范围内，93%的患者在 0.50 D 以内。线性回归分析显示，目标与实际等效球镜屈光度之间存在良好的相关性（R²=0.72）。无明显的术中或术后并发症。
植入 Sulcoflex IOL 是一种有效且可预测的选择，可提高术后屈光结果，并减少术后对距离的眼镜依赖。该 IOL 在所有眼中均具有良好的耐受性。
